On the Horizon >> Safety & Efficacy

Probiotics are Generally Regarded As Safe (GRAS) by regulatory authorities and live bacteria have been available to consumers for many years in dairy products.

The recognised safety and efficacy of Bif 35624 in treating IBS patients is a significant scientific milestone for the company as it clearly identifies the potential of this class of therapeutic in treating specific chronic diseases.

By demonstrating early evidence of clinical efficacy, the company can provide pharmaceutical partner companies with a significant advantage over conventional drug development.

AH can progress its probiotic based products to early Phase II proof of principle clinical trials in approximately 1/3 of the time of conventional pharmaceutical products.

The inherent safety profile of this class of therapeutic also reduces the risk of safety issues arising at late stage clinical trials or post marketing approval.